Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARALL: Veltuzumab and Epratuzumab with Chemotherapy for Relapsed/Refractory B-ALL
NCT01279707Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Jan 2010
- Primary completion
- Aug 2014
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of veltuzumab, epratuzumab in acute lymphoblastic leukemia (ALL), sponsored by Queen Mary University of London. Status: unknown.
02
Drugs
veltuzumabepratuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01279707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01279707.